Beta1 integrin modulation in pulmonary emphysema

Modulation of beta1 integrin has prevented cell death associated with injury in primary human lung cells.  AVIPERO’s research has also demonstrated efficacy of beta1 integrin modulation in inducing structural and functional repair and reversal of injury in animal models of severe emphysema.  Our findings have been recently published in Advances in Pharmacological Sciences (http://www.hindawi.com/journals/aps/aip/768720/)

Beta1 integrin modulation in Neurodegeneration

Modulation of beta1 integrin has prevented cell death induced by beta amyloid fibrils in primary human neurons.

AVIPERO’s research has also demonstrated efficacy of beta1 integrin modulation in inducing structural and motor functional repair and reversal of injury in animal models of Parkinson’s Disease.

Beta1 integrin modulation in Arthritis

Modulation of beta1 integrin has prevented cell death associated with injury in primary human chondrocytes (cartilage-derived cells).

AVIPERO’s research has also demonstrated efficacy of beta1 integrin modulation in inducing structural and functional repair and reversal of injury in animal models of arthritis.

Beta1 integrin modulation in cellular senescence (ageing)

AVIPERO’s research has also demonstrated efficacy of modulation of beta1 integrin in preventing not only cell death but also loss of proliferation associated with ageing AND injury.

We are uniquely positioned in the area of integrin therapeutics as we have proprietary background and exclusive access to the lead and its know-how for use in all therapeutic indications. Our intellectual property covers use of the target for tissue repair based on proof-of-concept efficacy data in lung emphysema, arthritis and in vitro amyloid beta-injury in addition to Parkinson’s disease models. AVIPERO is currently seeking finance for the process of humanization of the therapeutic antibody and detailed optimisation leading to filing for a micro-dosing clinical trial in 2 years.

Our current IP portfolio includes the following:

1. Application filed October, 2003 proceeded to PCT (WO2005037313) and national filing on April, 2006 in US, Europe, and Japan. This application protects the use of beta1 integrin in inducing tissue repair in general on basis of exemplification data in emphysema, arthritis, in vitro beta amyloid injury and Parkinson’s disease. http://www.wipo.int/pctdb/en/wo.jsp?WO=2005037313
2. Application filed February, 2007 proceeded to PCT with 2 divisional applications in UK and US (WO2008104808) and national filing in August 2009 covering the pharmacological and biological mechanism of action, efficacy in arthritis and neurodegeneration and assay methods. http://www.wipo.int/pctdb/en/wo.jsp?WO=2008104808. Application granted in UK.
3. Application filed September, 2011 covering the use of beta1 integrin in ageing.

The University of Manitoba has granted AVIPERO an exclusive license for all therapeutic uses of the selected hybridoma.

All IPs have been assigned to Rehab AlJamal-Naylor and Robert John Naylor.

Competing IP

• Beta1 integrin activation as a marker for asthma (USUS2008274482 and US2009061463)- Wisconsin Alumni Research Foundation.
• Activator for beta1 integrin (JP2008067616)- University of Science Tokyo.
• Peptides with beta1 Integrin Subunit Dependent Cell Adhesion Modulating Activity (WO9937669)- University of Minnesota.
• Methods of Inhibiting Amyloid Toxicity (US2003109435)- Elan Pharmaceuticals.
• Restoration of normal phenotype in cancer cells (US5846536)- The Regents of the University of California.
• Evaluation Methos and Method for Screening Skin Aging Improving Agent and Skin Aging Preventive (JP2010115131)- Kao Corp.